Literature DB >> 30129153

Effect of a functional variant of tumor necrosis factor-β gene in temporomandibular disorders: A pilot study.

Kaan Yerliyurt1, Ayse Feyda Nursal2, Akin Tekcan3, Nevin Karakus4, Mehmet K Tumer5, Serbulent Yigit4.   

Abstract

BACKGROUND: Temporomandibular disorders (TMD) are a group of conditions that cause chronic orofacial pain. The tumor necrosis factor β (TNF-β) is a proinflammatory cytokine that is involved in the various aspects of the inflammatory process including organization and maintenance, and in the arrangement of cells at the inflammation site. The purpose of this study was to evaluate the correlation between TNF-β +252A/G (rs909253) variant and susceptibility to TMD in a Turkish cohort.
METHODS: The study included 104 patients (26 males, 78 females) with TMD and 126 healthy controls (44 males, 82 females). The TNF-β +252A/G variant analysis was based on Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).
RESULTS: There was no deviation from HWA for TNF-β +252A/G variant in patient and control groups. There was significant difference in genotype and allele frequencies between patient group and control group in terms of TNF-β +252A/G variant, respectively (P = 0.010, 0.015). A significant increase in the TNF-β +252 AG genotype and G allele frequencies were observed in TMD patients compared to healthy controls. The individuals with GG genotype and G allele had an increased risk of developing TMD. A statistically significant association was observed when the patients were compared with the controls according to AA genotype vs AG+GG genotypes (P = 0.002, OR: 2.23, 95% CI:1.31-3.82). TNF-β +252A/G genotype distribution was associated with chewing problems (P = 0.046).
CONCLUSIONS: In conclusion, our results provided evidence that TNF-β +252A/G variant may contribute to TMD development in a Turkish cohort. Further studies are needed to confirm this observation.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  +252A/G; temporomandibular disorders; tumor necrosis factor β; variant

Mesh:

Substances:

Year:  2018        PMID: 30129153      PMCID: PMC6430349          DOI: 10.1002/jcla.22641

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  35 in total

1.  Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain.

Authors:  S Nordahl; P Alstergren; S Kopp
Journal:  J Oral Maxillofac Surg       Date:  2000-05       Impact factor: 1.895

2.  Effect of a functional variant of tumor necrosis factor-β gene in temporomandibular disorders: A pilot study.

Authors:  Kaan Yerliyurt; Ayse Feyda Nursal; Akin Tekcan; Nevin Karakus; Mehmet K Tumer; Serbulent Yigit
Journal:  J Clin Lab Anal       Date:  2018-08-20       Impact factor: 2.352

3.  Association of matrix metalloproteinase gene polymorphism with temporomandibular joint degeneration.

Authors:  Aline C Planello; Maria I G Campos; Carolina B Meloto; Rodrigo Secolin; Célia M Rizatti-Barbosa; Sergio R P Line; Ana P de Souza
Journal:  Eur J Oral Sci       Date:  2011-02       Impact factor: 2.612

4.  Influence of TNF-α-308 G/A gene polymorphism on temporomandibular disorder.

Authors:  Bruno D'Aurea Furquim; Lívia Maria Sales Pinto Flamengui; Carlos Eduardo Palanch Repeke; Franco Cavalla; Gustavo Pompermaier Garlet; Paulo César Rodrigues Conti
Journal:  Am J Orthod Dentofacial Orthop       Date:  2016-05       Impact factor: 2.650

5.  Lymphotoxin 252A>G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis.

Authors:  V F Panoulas; S N Nikas; J P Smith; K M J Douglas; P Nightingale; H J Milionis; G J Treharne; T E Toms; M D Kita; G D Kitas
Journal:  Ann Rheum Dis       Date:  2008-01-29       Impact factor: 19.103

6.  Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures.

Authors:  C Chenu; J Pfeilschifter; G R Mundy; G D Roodman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  Interleukin-6 family of cytokines as biochemical markers of osseous changes in the temporomandibular joint disorders.

Authors:  Keiseki Kaneyama; Natsuki Segami; Jun Sato; Masaaki Nishimura; Hiroshi Yoshimura
Journal:  Br J Oral Maxillofac Surg       Date:  2004-06       Impact factor: 1.651

8.  Association of Functional Polymorphisms in Matrix Metalloproteinase-9 and Glutathione S-Transferase T1 Genes with Temporomandibular Disorders.

Authors:  Natasa Milosevic; Nadja Nikolic; Igor Djordjevic; Ana Todorovic; Vojkan Lazic; Jelena Milasin
Journal:  J Oral Facial Pain Headache       Date:  2015

Review 9.  Biologic basis for interleukin-1 in disease.

Authors:  C A Dinarello
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

Review 10.  Reported concepts for the treatment modalities and pain management of temporomandibular disorders.

Authors:  Mieszko Wieckiewicz; Klaus Boening; Piotr Wiland; Yuh-Yuan Shiau; Anna Paradowska-Stolarz
Journal:  J Headache Pain       Date:  2015-12-07       Impact factor: 7.277

View more
  3 in total

1.  Effect of a functional variant of tumor necrosis factor-β gene in temporomandibular disorders: A pilot study.

Authors:  Kaan Yerliyurt; Ayse Feyda Nursal; Akin Tekcan; Nevin Karakus; Mehmet K Tumer; Serbulent Yigit
Journal:  J Clin Lab Anal       Date:  2018-08-20       Impact factor: 2.352

2.  Association of Estrogen Receptor 1 and Tumor Necrosis Factor α Polymorphisms with Temporomandibular Joint Anterior Disc Displacement without Reduction.

Authors:  Bartosz Dalewski; Agata Kamińska; Katarzyna Białkowska; Anna Jakubowska; Ewa Sobolewska
Journal:  Dis Markers       Date:  2020-10-12       Impact factor: 3.434

Review 3.  Genetic overlap between temporomandibular disorders and primary headaches: A systematic review.

Authors:  Diogo Cruz; Francisca Monteiro; Maria Paço; Manuel Vaz-Silva; Carolina Lemos; Miguel Alves-Ferreira; Teresa Pinho
Journal:  Jpn Dent Sci Rev       Date:  2022-02-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.